E. Lappi-blanco et al., Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized, HUMAN PATH, 30(10), 1999, pp. 1192-1196
Citations number
28
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Bronchiolitis obliterans organizing pneumonia (BOOP) and usual interstitial
pneumonia (UIP; ie, cryptogenic fibrosing alveolitis of mural type, CFA) a
re clinically and histologically distinguishable interstitial lung diseases
. Both contain intraluminal lesions of newly formed fibromyxoid connective
tissue. In BOOP, the fibromyxoid lesions are susceptible to complete revers
al, but in UIP they are supposed to participate in the remodeling of the in
terstitium. Our hypothesis was that capillarization of the intraluminal fib
romyxoid lesions is more frequent in BOOP compared with UIP. In this study,
we stained diagnostic thoracoscopic or open lung biopsy specimens of patie
nts with BOOP (n = 9) and UIP (n = 10) with antibodies against human lamini
n, von Willebrand factor, and CD34 to reveal the microvasculature of intral
uminal fibromyxoid lesions. Our results show that in BOOP there is abundant
capillarization in the newly formed intraluminal fibromyxoid lesions often
reminiscent of granulation tissue. The mean number of capillaries per area
unit (mm(2)) was 107 +/- SD 74 in samples stained for laminin, 103 +/- SD
46 for von Willebrand factor, and 63 +/- SD 36 for CD34. In marked contrast
, in UIP, the corresponding accounts were significantly lower, being 14 +/-
SD 15 for laminin (P < .003), 11 +/- SD 14 for von Willebrand factor (P <
.001) and 6 +/- SD 6 for CD34 (P < .001). The intraobserver (P < .001) and
interobserver correlations (P < .002) were highly significant, showing that
our results are reproducible. We conclude that the content and nature of t
he newly formed intraluminal connective tissue, for example, in the form of
vascular growth factors, are different in BOOP and in UIP, and this partly
leads to the different clinical course of these diseases. Copyright (C) 19
99 by W.B. Saunders Company.